Medtronic has announced FDA approval of its latest single-chamber implantable cardioverter defibrillators (ICDs) that feature the ability to detect atrial fibrillation (AFib). The technology allows for monitoring of recurrent, previously diagnosed AFib, as well as detection of undiagnosed and asymptomatic AFib.
Detection of AFib remains a challenge, as symptoms often appear seemingly randomly and last for a short time. Using external ECG monitors often misses events since these are typically worn for a relatively short time while AFib comes and goes as it likes. The frequency and length of detected AFib events are recorded and wirelessly shared with the patient’s cardiologist.
The Visia AF MRI ICD is designed for safety inside an MRI machine, as long as precautions are taken, and works along with Medtronic’s Sprint Quattro Secure MRI SureScan DF4 leads.
The devices also feature SmartShock 2.0 technology that reduces unnecessary shocks by being able to distinguish between dangerous and benign rhythms.